Boxer Capital Management’s Cullinan Therapeutics CGEM Stock Holding History
Bought
Maintained
Sold
Other funds holding CGEM
LCM
KCM
SL
Boxer Capital Management's CGEM Position: Q3 2026 in Review
Boxer Capital Management opened a new position in Cullinan Therapeutics (CGEM) in Q3 2026: 450,000 shares worth $6.91M. The stake represents 0.6% of the portfolio and ranks #24 among its holdings. This is a return to the name: Boxer Capital Management previously reported a position in CGEM as recently as Q4 2024.
Boxer Capital Management first reported a position in CGEM in Q1 2021 and has held it in 15 quarters since. The position peaked at $44.8M in Q1 2021. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.
- Boxer Capital Management held 450,000 shares of Cullinan Therapeutics worth $6.91M as of Q3 2026.
- Cullinan Therapeutics was a new Boxer Capital Management position in Q3 2026.
- Cullinan Therapeutics made up 0.6% of Boxer Capital Management's portfolio in Q3 2026, its #24 holding.
- Boxer Capital Management first reported a position in Cullinan Therapeutics in Q1 2021 and has held it in 15 quarters since.
- Boxer Capital Management's Cullinan Therapeutics position peaked at $44.8M in Q1 2021.
- 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.
Based on Boxer Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.